|
04.02.2025 13:57:05
|
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025. The programme is now concluded.
Since the announcement 27 January 2025, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 4,018,074 | 2,781,626,352 | |
| 27 January 2025 | 93,500 | 613.35 | 57,348,068 |
| 28 January 2025 | 93,488 | 616.54 | 57,639,187 |
| 29 January 2025 | 94,000 | 615.03 | 57,812,465 |
| 30 January 2025 | 99,977 | 605.03 | 60,488,801 |
| 31 January 2025 | 100,000 | 611.79 | 61,179,203 |
| 3 February 2025 | 100,455 | 598.38 | 60,109,995 |
| Accumulated under the programme | 4,599,494 | 3,136,204,070 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 25,947,151 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 4 February 2025, Novo Nordisk has since 6 February 2024 repurchased a total 24,802,593 B shares at an average share price of DKK 806.37 per B share equal to a transaction value of DKK 19,999,997,948.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Instagram, X, LinkedIn and
YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 6 / 2025
Attachments
Nachrichten zu Novo Nordisk
|
09:28 |
Handel in Europa: STOXX 50-Börsianer greifen zum Start des Montagshandels zu (finanzen.ch) | |
|
21.03.25 |
Schwache Performance in Europa: STOXX 50 zum Ende des Freitagshandels im Minus (finanzen.ch) | |
|
21.03.25 |
Schwache Performance in Europa: STOXX 50 nachmittags in der Verlustzone (finanzen.ch) | |
|
21.03.25 |
Freitagshandel in Europa: Das macht der STOXX 50 am Mittag (finanzen.ch) | |
|
21.03.25 |
Schwache Performance in Europa: STOXX 50 verbucht zum Start des Freitagshandels Abschläge (finanzen.ch) | |
|
20.03.25 |
Zurückhaltung in Europa: STOXX 50 letztendlich leichter (finanzen.ch) | |
|
20.03.25 |
STOXX 50-Handel aktuell: So performt der STOXX 50 am Nachmittag (finanzen.ch) | |
|
20.03.25 |
Börse Europa: STOXX 50 fällt zurück (finanzen.ch) |
Analysen zu Novo Nordisk
| 08:33 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 21.03.25 | Novo Nordisk Buy | UBS AG | |
| 17.03.25 | Novo Nordisk Buy | UBS AG | |
| 14.03.25 | Novo Nordisk Buy | UBS AG | |
| 12.03.25 | Novo Nordisk Underperform | Jefferies & Company Inc. |
Warren Buffett – Hot Picks – Wall Street Live mit Tim Schäfer
In diesem spannenden Video spricht Tim Schäfer über die Investment-Philosophie von Warren Buffett und warum langfristiges Buy & Hold auch heute noch funktioniert. Gemeinsam werfen wir einen Blick auf Berkshire Hathaway, die Lieblingsaktie von Tim, und analysieren die grössten Positionen des Star-Investors – von Apple über Coca-Cola bis hin zu Occidental Petroleum.
✅ Welche Dividendenaktien lohnen sich wirklich?
✅ Warum Buffett Milliarden in Cash hält
✅ Wie du dein Depot stabil und renditestark aufbaust
✅ Welche Titel Buffett kürzlich reduziert – und wo er verstärkt einsteigt
✅ Tipps von Tim Schäfer aus erster Hand – direkt von der Wall Street!
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Novo Nordisk | 66.29 | -2.61% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Hoffen auf moderatere Zollpolitik: SMI tiefer -- DAX mit Gewinnen -- US-Börsen vor festem Start -- Asiens Börsen schliessen mehrheitlich in GrünDer heimische Aktienmarkt präsentiert sich am Montag mit einer negativen Tendenz, während der deutsche Aktienmarkt mit Zuwächsen in die Woche startet. An den US-Börsen dürften zum Wochenstart die Bullen das Ruder übernehmen. An den Märkten in Fernost ging es zum Wochenstart mehrheitlich nach oben.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |